Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial

Dr. Savannah Partridge’s study titled “Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial” was published in the RSNA Radiology Journals and featured on AuntMinnie.com. The study found that change in breast tumor apparent diffusion coefficient on breast MRI performed at the mid-treatment time point (12 weeks) of neoadjuvant chemotherapy predicted complete pathologic response at the time of definitive breast surgery after completion of chemotherapy.